Page 72 - Amgen News Today

In this article, we will be taking a look at the 20 fastest growing health tech companies in the world.

Bank of New Hampshire trimmed its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 19.8% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,836 shares of the medical research company’s stock after selling 454 shares during the period. Bank of New Hampshire’s holdings in Amgen […]

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr....

Bank of New Hampshire cut its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 19.8% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 1,836 shares of the medical research company’s stock after selling 454 shares during the quarter. Bank of New Hampshire’s holdings in Amgen were worth $529,000 as of its most […]

Investegate announcements from EQS-News: CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

Parkside Financial Bank & Trust boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 15.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 3,567 shares of the medical research company’s stock after purchasing an additional 480 shares during the period. Parkside Financial […]

Issuer: CureVac / Key word: Annual Results CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update 24.04.2024 / 13:06...

Investegate announcements from EQS-News: CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

At Amgen, our unique real-world evidence capabilities in our Center for Observational Research are breaking new ground in our knowledge of plaque psoriasis and psoriatic arthritis. Cynthia Deignan and...

Parkside Financial Bank & Trust grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 15.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,567 shares of the medical research company’s stock after buying an additional 480 shares […]